Compare RBC & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBC | PODD |
|---|---|---|
| Founded | 1919 | 2000 |
| Country | United States | United States |
| Employees | 5334 | N/A |
| Industry | Metal Fabrications | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0B | 17.0B |
| IPO Year | N/A | 2007 |
| Metric | RBC | PODD |
|---|---|---|
| Price | $600.64 | $171.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 21 |
| Target Price | ★ $510.00 | $341.48 |
| AVG Volume (30 Days) | 154.9K | ★ 902.9K |
| Earning Date | 05-15-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $15.20 | $24.55 |
| Revenue Next Year | $12.36 | $19.18 |
| P/E Ratio | $64.90 | ★ $46.25 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $337.43 | $158.35 |
| 52 Week High | $607.45 | $354.88 |
| Indicator | RBC | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 59.30 | 26.93 |
| Support Level | $567.20 | N/A |
| Resistance Level | $607.45 | $205.95 |
| Average True Range (ATR) | 14.71 | 7.04 |
| MACD | -0.54 | -1.91 |
| Stochastic Oscillator | 82.57 | 26.32 |
RBC Bearings is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: industrial, which generates the most revenue, and aerospace and defense. The A&D segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.